Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
University of Washington
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Lyell Immunopharma, Inc.
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
AIDS Malignancy Consortium
Yale University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Genmab
National Cancer Institute (NCI)
Genmab
AstraZeneca
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Gilead Sciences
Henan Cancer Hospital
Chipscreen Biosciences, Ltd.
Genmab
Genmab
University of Washington
Affiliated Hospital to Academy of Military Medical Sciences
University College, London
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Hackensack Meridian Health
Artiva Biotherapeutics, Inc.
University Hospital, Caen
Alliance for Clinical Trials in Oncology